CEDAR KNOLLS, N.J., Feb. 15, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the fertilized egg yolk-based product that helps build lean muscle in conjunction with resistance training, announced today that it will showcase Fortetropin® at the Arnold Fitness EXPO to be held during the Arnold Sports Festival March 2-4, 2018, at the Greater Columbus Convention Center in Columbus, Ohio.
Arnold Fitness EXPO attendees are encouraged to visit booth #513 to sample the Qurr® line of products, available in delicious powders, puddings and shakes. Each product contains MYOS' proprietary ingredient Fortetropin®, which is clinically shown to increase lean muscle size and mass. Fortetropin® is a unique bioactive composition derived from fertilized egg yolk and processed using patented technology, thereby retaining its nutrient-dense nature and biological integrity. Attendees will also be able to purchase Qurr products at special EXPO discounted prices.
Joseph Mannello, Chief Executive Officer of MYOS, commented, "The "Arnold" is the most iconic event in the fitness world; over 200,000 people flock to the show annually, which features 20,000 athletes from 80 nations, non-stop competitions and entertainment over four days, and over 1,000 booths of fitness equipment, apparel and nutrition. We believe Fortetropin® is a perfect fit for this crowd and the Arnold Sports Festival, an excellent platform to fast-track brand awareness."
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin® has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin® has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr® products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
Porter LeVay & Rose
Michael Porter, President
SOURCE MYOS RENS Technology